HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION
Clinical trials for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for tough breast cancer
Disease control CompletedThis study tested the safety of combining two drugs, alpelisib and fulvestrant, in 40 men and post-menopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to track side effects. The …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis study tested a drug called alpelisib combined with hormone therapy (fulvestrant or letrozole) in 383 people with advanced breast cancer that has a specific genetic change (PIK3CA mutation). The goal was to see how many patients were alive without their cancer getting worse a…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC